PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33733978-6	2021	The combination of lenalidomide plus dexamethasone with an anti-CD38 MoAb such as daratumumab and a proteasome inhibitor such as bortezomib is currently one of the most potent first line treatment regimens for MM.	Lenalidomide	19-31	CD38 molecule	Homo sapiens	64-68	
31043801-10	2019	Bortezomib (40 nmol/L, 24 hours) and lenalidomide (3,200 nmol/L, 24 hours) effectively removed CD38+CD138+ cells from peripheral mononuclear cells.	Lenalidomide	37-49	CD38 molecule	Homo sapiens	95-99	
32435618-6	2020	Among the novel anti-myeloma IT-based agents, anti-CD38 monoclonal antibodies (mAbs) are now becoming the new backbone of treatment for NTE patients, in association with lenalidomide and dexamethasone.	Lenalidomide	170-182	CD38 molecule	Homo sapiens	51-55	
28249894-4	2017	CD38 levels and the percentages of CD38high Tregs are increased by lenalidomide and pomalidomide.	Lenalidomide	67-79	CD38 molecule	Homo sapiens	0-4	
30079070-1	2018	Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortezomib plus dexamethasone, and tolerable side effects.	Lenalidomide	278-290	CD38 molecule	Homo sapiens	55-59	
30826127-8	2019	Preclinical and clinical studies have demonstrated that CD38-targeting antibodies have synergistic activity with several other anti-cancer drugs, including various agents with immune stimulating activity, such as lenalidomide and pomalidomide, as well as PD1/PD-L1 inhibitors.	Lenalidomide	213-225	CD38 molecule	Homo sapiens	56-60	
29702148-8	2018	Preclinical and clinical studies have demonstrated that CD38-targeting antibodies have synergistic activity with several other anti-cancer drugs, including various agents with immune stimulating activity, such as lenalidomide and pomalidomide, as well as PD1/PD-L1 inhibitors.	Lenalidomide	213-225	CD38 molecule	Homo sapiens	56-60	
28249894-4	2017	CD38 levels and the percentages of CD38high Tregs are increased by lenalidomide and pomalidomide.	Lenalidomide	67-79	CD38 molecule	Homo sapiens	35-39	
25398450-0	2015	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.	Lenalidomide	131-143	CD38 molecule	Homo sapiens	54-58	
27611189-7	2016	Furthermore, anti-CD38-IFNalpha(attenuated) is more efficacious than standard MM treatments (lenalidomide, bortezomib, dexamethasone) and exhibits strong synergy with lenalidomide and with bortezomib in xenograft models.	Lenalidomide	93-105	CD38 molecule	Homo sapiens	18-22	
27611189-7	2016	Furthermore, anti-CD38-IFNalpha(attenuated) is more efficacious than standard MM treatments (lenalidomide, bortezomib, dexamethasone) and exhibits strong synergy with lenalidomide and with bortezomib in xenograft models.	Lenalidomide	167-179	CD38 molecule	Homo sapiens	18-22	
27668268-4	2015	Lenalidomide upregulated critical T cell activation markers and costimulatory molecules (CD28, CD38, CD40L, CD69, ICOS), especially within the central memory CTL subset of XBP1-CTL, while decreasing TCRalphabeta and T cell checkpoint blockade (CTLA-4, PD-1).	Lenalidomide	0-12	CD38 molecule	Homo sapiens	95-99	
27668268-5	2015	Lenalidomide increased the anti-tumor activities of XBP1-CTL memory subsets, which were associated with expression of Th1 transcriptional regulators (T-bet, Eomes) and Akt activation, thereby resulting in enhanced IFN-gamma production, granzyme B upregulation and specific CD28/CD38-positive and CTLA-4/PD-1-negative cell proliferation.	Lenalidomide	0-12	CD38 molecule	Homo sapiens	278-282